secwatch.observer — SEC 8-K summary
======================================

Issuer:     TENAX THERAPEUTICS, INC. (TENX)
CIK:        0000034956
Form:       8-K
Filed at:   2024-11-13T23:59:59+00:00
Accession:  0001654954-24-014203
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tenax Therapeutics Q3 net loss $4.0M; raised $100M private placement
--------------------------------------------------------------------

- Net loss of $4.0M for Q3 2024 vs $2.0M in Q3 2023; R&D expenses $3.1M (up from $1.1M).
- Cash, cash equivalents and investments $98.3M as of Sept 30, 2024, vs $9.8M at Dec 31, 2023.
- Closed private placement in Aug 2024 yielding approximately $100M gross proceeds.
- Phase 3 LEVEL study for levosimendan ongoing: 52 investigative sites initiated, enrolling patients.
- Cash runway projected through end of 2027 based on current operating plan.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/34956/000165495424014203/0001654954-24-014203-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/34956/000165495424014203/tenx_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-24-014203

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer